221 related articles for article (PubMed ID: 21347685)
1. Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
Vangsted AJ; Klausen TW; Abildgaard N; Andersen NF; Gimsing P; Gregersen H; Nexø BA; Vogel U
Ann Hematol; 2011 Oct; 90(10):1173-81. PubMed ID: 21347685
[TBL] [Abstract][Full Text] [Related]
2. A functional polymorphism in the promoter region of the IL1B gene is associated with risk of multiple myeloma.
Vangsted AJ; Nielsen KR; Klausen TW; Haukaas E; Tjønneland A; Vogel U
Br J Haematol; 2012 Aug; 158(4):515-8. PubMed ID: 22540426
[TBL] [Abstract][Full Text] [Related]
3. NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma.
Varga G; Mikala G; Andrikovics H; Koszarska M; Balassa K; Ádám E; Kozma A; Tordai A; Masszi T
Br J Haematol; 2015 Mar; 168(5):679-88. PubMed ID: 25363231
[TBL] [Abstract][Full Text] [Related]
4. Novel agents for relapsed and/or refractory multiple myeloma.
Thomas SK; Richards TA; Weber DM
Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
[TBL] [Abstract][Full Text] [Related]
5. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
6. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
7. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
[TBL] [Abstract][Full Text] [Related]
8. Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
Krejci M; Gregora E; Straub J; Minarik J; Scudla V; Adam Z; Krivanova A; Pour L; Zahradova L; Buchler T; Mayer J; Hajek R
Ann Hematol; 2011 Dec; 90(12):1441-7. PubMed ID: 21380511
[TBL] [Abstract][Full Text] [Related]
9. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
Takatoku M; Noborio-Hatano K; Takahashi S; Kikuchi S; Mori M; Muroi K; Komatsu N; Ozawa K
Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823
[TBL] [Abstract][Full Text] [Related]
10. The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP.
Vangsted AJ; Klausen TW; Gimsing P; Abildgaard N; Andersen NF; Gregersen H; Nexø BA; Vogel UB
Ann Hematol; 2011 Jun; 90(6):675-84. PubMed ID: 21046104
[TBL] [Abstract][Full Text] [Related]
11. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.
Vangsted AJ; Søeby K; Klausen TW; Abildgaard N; Andersen NF; Gimsing P; Gregersen H; Vogel U; Werge T; Rasmussen HB
BMC Cancer; 2010 Aug; 10():404. PubMed ID: 20684753
[TBL] [Abstract][Full Text] [Related]
12. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
13. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
14. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
Satoh M; Oguro R; Yamanaka C; Takada K; Matsuura Y; Akiba T; Aotsuka N; Tani Y; Wakita H
J Pharm Pharm Sci; 2011; 14(1):78-89. PubMed ID: 21501555
[TBL] [Abstract][Full Text] [Related]
15. A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support.
Vangsted AJ; Klausen TW; Gimsing P; Andersen NF; Abildgaard N; Gregersen H; Vogel U
Haematologica; 2009 Sep; 94(9):1274-81. PubMed ID: 19734419
[TBL] [Abstract][Full Text] [Related]
16. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
[TBL] [Abstract][Full Text] [Related]
18. Management of older patients with multiple myeloma.
Gay F; Palumbo A
Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
[TBL] [Abstract][Full Text] [Related]
19. Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone.
Du J; Yuan Z; Zhang C; Fu W; Jiang H; Chen B; Hou J
Leuk Res; 2010 Nov; 34(11):1453-8. PubMed ID: 20122728
[TBL] [Abstract][Full Text] [Related]
20. The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT.
Vangsted AJ; Klausen TW; Ruminski W; Gimsing P; Andersen NF; Gang AO; Abildgaard N; Knudsen LM; Nielsen JL; Gregersen H; Vogel U
Bone Marrow Transplant; 2009 Apr; 43(7):539-45. PubMed ID: 18997828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
